Targeted delivery of rosuvastatin enhances treatment of hyperhomocysteinemia-induced atherosclerosis using macrophage membrane-coated nanoparticles

• Main Authors: Dayue Liu (Author), Anning Yang (Author), Yulin Li (Author), Zhenxian Li (Author), Peidong You (Author), Hongwen Zhang (Author), Shangkun Quan (Author), Yue Sun (Author), Yaling Zeng (Author), Shengchao Ma (Author), Jiantuan Xiong (Author), Yinju Hao (Author), Guizhong Li (Author), Bin Liu (Author), Huiping Zhang (Author), Yideng Jiang (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Rosuvastatin (RVS) is an excellent drug with anti-inflammatory and lipid-lowering properties in the academic and medical fields. However, this drug faces a series of challenges when used to treat atherosclerosis caused by hyperhomocysteinemia (HHcy), including high oral dosage, poor targeting, and l...